Ocugen Partner Reports Strong Phase 3 Results for Coronavirus Vaccine

Ocugen Partner Reports Strong Phase 3 Results for Coronavirus Vaccine
Eric Volkman, The Motley Fool
·2 min read

A new coronavirus vaccine candidate could soon be authorized for use, if its excellent clinical results are any indication. Ocugen (NASDAQ: OCGN) has unveiled the results of a phase 3 clinical trial of the Covaxin vaccine conducted by its co-development partner Bharat Biotech. Ocugen made an important and very relevant point about the timing of the study.